- Home
- Equities - Stocks - Shares
- Company Press Releases
- Desert Control AS: Desert Control Q3 2024 Report and Interim Financial Results | Webcast Presentation 15 November 2024 10:00 (Updated Link For The Webcast)
Desert Control AS: Desert Control Q3 2024 Report and Interim Financial Results | Webcast presentation 15 November 2024 10:00 (Updated link for the webcast)
14 Nov 2024 09:38 CET
Issuer
Desert Control AS
Sandnes, Norway 14 November 2024:
Desert Control Q3 2024 Report and Interim Financial Result will be released on
Friday 15 November 2024 at 06.30 AM Central European Time (Oslo)
The Q3 Report and presentation will be made available
at https://www.desertcontrol.com/investors.
A webcast presentation in English will be hosted on Friday 15 November 2024 at
10.00 AM Central European Time.
Registration:
https://go.desertcontrol.com/Q3-2024
After the presentation, there will be a Q&A session. Questions can be submitted
in advance to leonard.chaparian@desertcontrol.com.
For more information, please contact:
Ole Kristian Sivertsen
President and Group CEO
Email: oks@desertcontrol.com
Mobile: +47 957 77 777
Leonard Chaparian
Chief Financial Officer
Email: leonard.chaparian@desertcontrol.com
Mobile: +47 90 66 55 40
About Desert Control:
Desert Control specializes in climate-smart AgTech solutions to combat
desertification, soil degradation, and water scarcity. Its patented Liquid
Natural Clay (LNC) restores and enhances soil ecosystems to reduce water usage
and improve the efficiency of fertilizers and natural resources for agriculture,
forests, and green landscapes. LNC enables sandy and arid soil to retain water
and nutrients, thus increasing crop yields, plant health, and ecosystem
resilience while preserving water and natural resources by up to 50%.
For more information about Desert Control, visit https://www.desertcontrol.com
More information:
Access the news on Oslo Bors NewsWeb site
Source
Desert Control AS
Provider
Oslo Børs Newspoint
Company Name
DESERT CONTROL AS
ISIN
NO0010963275
Symbol
DSRT
Market
Euronext Growth